Sept. 10, 2025
| Today’s news and insights for biopharma leaders
The drugmaker’s new CEO said the moves will help the company be more agile as it deals with competition in the obesity market and a declining stock price.
|
J&J executives have said they expect the therapy, Inlexzo, to become a future blockbuster and generate sales that significantly outstrip Wall Street forecasts.
|
UPDATED
Following an executive order from President Trump, the FDA plans to “aggressively deploy its available enforcement tools” to police direct-to-consumer drug ads.
|
Driving precision oncology with integrated biomarker testing that delivers results.
|
News roundup
Kriya’s $320 million raise ranks as one of the year’s largest private funding rounds. Elsewhere, a Genentech veteran joined Amgen and Merck and Daiichi touted results for a new kind of antibody-drug conjugate.
|
Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.
|
The Future of Pharma: Innovation in Action
|
|
From Our Library
Playbook
Custom content for Cardinal Health
|
Trendline
Supported by Advanced Clinical
|
Playbook
Custom content for WCG
|
Infographic
Custom content for Woven | | 
